Enanta Pharmaceuticals (ENTA) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a strong-buy rating to a hold rating in a report released on Tuesday.

According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

A number of other equities research analysts have also recently issued reports on ENTA. Royal Bank of Canada reaffirmed a hold rating and set a $80.00 target price on shares of Enanta Pharmaceuticals in a research report on Wednesday, April 4th. ValuEngine raised Enanta Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Monday, April 2nd. JPMorgan Chase cut Enanta Pharmaceuticals from an overweight rating to a neutral rating in a research report on Thursday, February 8th. BidaskClub raised Enanta Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Wednesday, March 14th. Finally, TheStreet raised Enanta Pharmaceuticals from a c+ rating to a b- rating in a research report on Wednesday, December 13th. Four analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $57.80.



NASDAQ:ENTA opened at $85.98 on Tuesday. Enanta Pharmaceuticals has a 52 week low of $29.46 and a 52 week high of $95.91. The company has a market capitalization of $1,623.68, a P/E ratio of 44.13 and a beta of 1.07.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.73. Enanta Pharmaceuticals had a return on equity of 13.33% and a net margin of 26.35%. The firm had revenue of $38.11 million for the quarter, compared to the consensus estimate of $27.26 million. analysts expect that Enanta Pharmaceuticals will post 0.86 EPS for the current fiscal year.

In other Enanta Pharmaceuticals news, Treasurer Paul J. Mellett sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $86.48, for a total transaction of $778,320.00. Following the completion of the sale, the treasurer now owns 96,458 shares of the company’s stock, valued at $8,341,687.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.56% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in ENTA. BlackRock Inc. boosted its position in shares of Enanta Pharmaceuticals by 4.3% in the fourth quarter. BlackRock Inc. now owns 2,343,593 shares of the biotechnology company’s stock valued at $137,521,000 after acquiring an additional 97,054 shares during the period. First Manhattan Co. boosted its position in shares of Enanta Pharmaceuticals by 14.5% in the fourth quarter. First Manhattan Co. now owns 1,084,200 shares of the biotechnology company’s stock valued at $63,620,000 after acquiring an additional 137,100 shares during the period. Farallon Capital Management LLC boosted its position in shares of Enanta Pharmaceuticals by 124.3% in the fourth quarter. Farallon Capital Management LLC now owns 925,000 shares of the biotechnology company’s stock valued at $54,279,000 after acquiring an additional 512,667 shares during the period. Renaissance Technologies LLC boosted its position in shares of Enanta Pharmaceuticals by 13.3% in the fourth quarter. Renaissance Technologies LLC now owns 771,600 shares of the biotechnology company’s stock valued at $45,277,000 after acquiring an additional 90,500 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Enanta Pharmaceuticals by 1.4% in the third quarter. Dimensional Fund Advisors LP now owns 562,394 shares of the biotechnology company’s stock valued at $26,320,000 after acquiring an additional 7,617 shares during the period. 73.25% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://dakotafinancialnews.com/2018/04/14/enanta-pharmaceuticals-enta-downgraded-by-zacks-investment-research.html.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply